Real‐world barriers to health care utilization among people living with migraine: Insights from the All of Us Research Program
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | Idris Demirsoy, Richard B. Lipton, Ali Ezzati |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2025
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study
por: Devin Teichrow, et al.
Publicado: (2026)
por: Devin Teichrow, et al.
Publicado: (2026)
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
por: Rikki Mangrum, et al.
Publicado: (2024)
por: Rikki Mangrum, et al.
Publicado: (2024)
Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study
por: Dawn C. Buse, et al.
Publicado: (2026)
por: Dawn C. Buse, et al.
Publicado: (2026)
Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society
por: Todd J. Schwedt, et al.
Publicado: (2025)
por: Todd J. Schwedt, et al.
Publicado: (2025)
Ubrogepant users' real‐world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study
por: Anand R. Shewale, et al.
Publicado: (2024)
por: Anand R. Shewale, et al.
Publicado: (2024)
Integrating gepants into clinical practice for the acute treatment of migraine
por: Richard B. Lipton, et al.
Publicado: (2026)
por: Richard B. Lipton, et al.
Publicado: (2026)
A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
por: David Kudrow, et al.
Publicado: (2025)
por: David Kudrow, et al.
Publicado: (2025)
Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
por: Richard B. Lipton, et al.
Publicado: (2025)
por: Richard B. Lipton, et al.
Publicado: (2025)
Prevalence and burden of migraine in the United States: A systematic review
por: Fred Cohen, et al.
Publicado: (2024)
por: Fred Cohen, et al.
Publicado: (2024)
Do patients with migraine and obesity receive different treatments? Insights from real‐world data
por: Keshet Pardo, et al.
Publicado: (2025)
por: Keshet Pardo, et al.
Publicado: (2025)
No differences in subcortical volume between people with and without migraine: A REFORM study
por: Basit Ali Chaudhry, et al.
Publicado: (2025)
por: Basit Ali Chaudhry, et al.
Publicado: (2025)
Maternal and child mental health and incident migraine in adolescence: An “All Our Families” prospective cohort study
por: Kirsten Sjonnesen, et al.
Publicado: (2026)
por: Kirsten Sjonnesen, et al.
Publicado: (2026)
Unmet treatment needs in migraine: Results of the OVERCOME (US) study
por: Susan Hutchinson, et al.
Publicado: (2026)
por: Susan Hutchinson, et al.
Publicado: (2026)
Counting the cost: How migraine shapes lives and economies
por: Risako Shirane, et al.
Publicado: (2025)
por: Risako Shirane, et al.
Publicado: (2025)
Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi‐country results from the CaMEO‐I study
por: Dawn C. Buse, et al.
Publicado: (2024)
por: Dawn C. Buse, et al.
Publicado: (2024)
Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME ( US ) study
por: Dawn C. Buse, et al.
Publicado: (2025)
por: Dawn C. Buse, et al.
Publicado: (2025)
Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
por: Stephen D. Silberstein, et al.
Publicado: (2024)
por: Stephen D. Silberstein, et al.
Publicado: (2024)
Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing
por: Richard B. Lipton, et al.
Publicado: (2025)
por: Richard B. Lipton, et al.
Publicado: (2025)
What a long strange trip it's been: Reflections on serial snapshots of migraine prevalence and burden in the United States
por: Fred Cohen, et al.
Publicado: (2025)
por: Fred Cohen, et al.
Publicado: (2025)
Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME ( US ) study
por: Jessica Ailani, et al.
Publicado: (2026)
por: Jessica Ailani, et al.
Publicado: (2026)
Navigating the patient journey in migraine prevention: An American Migraine Foundation position paper
por: Lawrence C. Newman, et al.
Publicado: (2025)
por: Lawrence C. Newman, et al.
Publicado: (2025)
Cardiovascular risk and triptan usage among patients with migraine
por: Ido Peles, et al.
Publicado: (2025)
por: Ido Peles, et al.
Publicado: (2025)
Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
por: Richard B. Lipton, et al.
Publicado: (2025)
por: Richard B. Lipton, et al.
Publicado: (2025)
Challenges and opportunities for estimating and assessing migraine prevalence, incidence and impact across study populations and methodologies: Bridging global and United States findings
por: Fred Cohen, et al.
Publicado: (2024)
por: Fred Cohen, et al.
Publicado: (2024)
Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
por: Samuel K. Peasah, et al.
Publicado: (2024)
por: Samuel K. Peasah, et al.
Publicado: (2024)
Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
por: Graham A. McLeod, et al.
Publicado: (2025)
por: Graham A. McLeod, et al.
Publicado: (2025)
Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment
por: Joanna K. Bougie, et al.
Publicado: (2024)
por: Joanna K. Bougie, et al.
Publicado: (2024)
The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
por: Yunus Emre Meydanal, et al.
Publicado: (2025)
por: Yunus Emre Meydanal, et al.
Publicado: (2025)
The impact of the migraine treatment onabotulinumtoxinA on inflammatory and pain responses: Insights from an animal model
por: Philip Victor Reducha, et al.
Publicado: (2024)
por: Philip Victor Reducha, et al.
Publicado: (2024)
Cognitive symptoms in veterans with migraine or traumatic brain injury: A Million Veteran Program study
por: Matthew S. Herbert, et al.
Publicado: (2024)
por: Matthew S. Herbert, et al.
Publicado: (2024)
Habitual caffeinated beverage consumption and headaches among adults with episodic migraine: A prospective cohort study
por: Maggie R. Mittleman, et al.
Publicado: (2024)
por: Maggie R. Mittleman, et al.
Publicado: (2024)
Correction to “Smartphone‐delivered progressive muscle relaxation for the treatment of migraine in primary care: A randomized controlled trial”
Publicado: (2025)
Publicado: (2025)
Heavy metal and trace element alterations in patients during a migraine attack
por: Sevilay Vural, et al.
Publicado: (2024)
por: Sevilay Vural, et al.
Publicado: (2024)
Perceptions of health, cognition, and pain among middle‐aged and older adults with migraine: A population‐based cross‐sectional study examining findings from the Canadian Longitudinal Study on Aging
por: Makenna K. N. Jensen, et al.
Publicado: (2025)
por: Makenna K. N. Jensen, et al.
Publicado: (2025)
Magnetoencephalography studies in migraine and headache disorders: A systematic review
por: Raghavan Gopalakrishnan, et al.
Publicado: (2024)
por: Raghavan Gopalakrishnan, et al.
Publicado: (2024)
Parental mental health and migraine in youth: An evolving story historically plagued with sparse and inadequate literature and mother‐blaming
por: Serena L. Orr
Publicado: (2024)
por: Serena L. Orr
Publicado: (2024)
Evaluating associations of migraine‐related vertigo
por: Nazia Karsan, et al.
Publicado: (2025)
por: Nazia Karsan, et al.
Publicado: (2025)
Differential impact of migraine on severe maternal morbidity and postpartum readmissions: Insights from a national cohort study
por: Michelle T. Tram, et al.
Publicado: (2026)
por: Michelle T. Tram, et al.
Publicado: (2026)
Rising migraine incidence in adolescents despite stable prevalence in the US : A call for further investigation
por: Ali Reza Tavasoli, et al.
Publicado: (2024)
por: Ali Reza Tavasoli, et al.
Publicado: (2024)
Afterimage duration differs for migraine with or without aura
por: Florian Rimmele, et al.
Publicado: (2025)
por: Florian Rimmele, et al.
Publicado: (2025)
Ejemplares similares
-
Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study
por: Devin Teichrow, et al.
Publicado: (2026) -
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
por: Rikki Mangrum, et al.
Publicado: (2024) -
Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study
por: Dawn C. Buse, et al.
Publicado: (2026) -
Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society
por: Todd J. Schwedt, et al.
Publicado: (2025) -
Ubrogepant users' real‐world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study
por: Anand R. Shewale, et al.
Publicado: (2024)